The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
One step forward, two steps back for biotech.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.